Arminen S L, Ikonen U, Pulkkinen P, Leinonen E, Mahlanen A, Koponen H, Kourula K, Ryyppö J, Korpela V, Lehtonen M L
Rauha Hospital, Finland.
Acta Psychiatr Scand. 1994 Jun;89(6):382-9. doi: 10.1111/j.1600-0447.1994.tb01533.x.
Fifty-seven inpatients with major depression (DSM-III-R) entered a 12-week study comparing paroxetine and imipramine. Trends (not reaching statistical significance) in favour of paroxetine were seen on the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Asberg Depression Rating Scale (MADRS). The UKU Side Effect Rating Scale showed a significant difference in favour of paroxetine on reduced salivation. Global evaluation of side effect symptoms showed that significantly more paroxetine patients had no side effects, both in the investigators' and the patients' opinion. These results are in line with previous findings of paroxetine being an effective and well tolerated antidepressant.
57名重度抑郁症（DSM-III-R）住院患者参与了一项为期12周的研究，比较帕罗西汀和丙咪嗪的疗效。在汉密尔顿抑郁量表（HDRS）和蒙哥马利-阿斯伯格抑郁量表（MADRS）上，观察到了有利于帕罗西汀的趋势（未达到统计学显著性）。UKU副作用评定量表显示，在减少流涎方面，帕罗西汀有显著差异。对副作用症状的总体评估表明，无论是研究者还是患者的观点，都有显著更多的帕罗西汀患者没有副作用。这些结果与之前关于帕罗西汀是一种有效且耐受性良好的抗抑郁药的研究结果一致。
